知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

21 records (took 0.018 seconds)

    Intrinsically-safe battery power supply for underground mining
    1.
    发明申请
    Intrinsically-safe battery power supply for underground mining 审中-公开
    用于地下采矿的本质安全电池电源

    公开(公告)号：US20050186471A1

    公开(公告)日：2005-08-25

    申请号：US11042371

    申请日：2005-01-25

    Applicant: Jens Titschert ,  Norbert Schwarz ,  Jorg Wagener

    Inventor： Jens Titschert ,  Norbert Schwarz ,  Jorg Wagener

    IPC: H01M2/02 ,  E21F9/00 ,  E21F17/04 ,  H01M2/10 ,  H01M2/34 ,  H01M10/052 ,  H01M10/34 ,  H01M10/36 ,  H01M10/46 ,  H02J7/00

    CPC classification number: H01M2/1094 ,  H01M10/052 ,  Y02E60/122

    Abstract: An intrinsically-safe battery power supply for electrical equipment in underground mining and in other areas exposed to the danger of explosion is disclosed. The power supply includes at least one chargeable storage battery cell disposed in a battery housing. At least one storage battery cell comprises a chargeable lithium storage battery cell and the battery housing is configured to be pressure-resistant and to receive all lithium storage battery cells in a manner so as to be protected from explosion. The pressure-resistant configuration of the battery housing enables the use of lithium storage battery cells in underground mining. Once the battery power supply fulfils all requirements of ignition protection certification, even modern types of lithium storage battery cell can be disposed in the battery housing.

    Abstract translation: 公开了一种用于地下采矿和其他暴露于爆炸危险区域的电气设备的本质安全电池电源。 电源包括设置在电池壳体中的至少一个可充电蓄电池。 至少一个蓄电池单元包括可充电的锂蓄电池单元，并且所述电池壳体被配置为耐压并且以能够防止爆炸的方式接收所有锂蓄电池单元。 电池壳体的耐压构造使得能够在地下采矿中使用锂蓄电池。 一旦电池电源满足点火保护认证的所有要求，即使现代类型的锂蓄电池可以放置在电池外壳中。

    Prostaglandin-I.sub.2 derivatives
    5.
    发明授权
    Prostaglandin-I.sub.2 derivatives 失效
    前列腺素I2衍生物

    公开(公告)号：US4191694A

    公开(公告)日：1980-03-04

    申请号：US928126

    申请日：1978-07-26

    Applicant: Werner Skuballa ,  Bernd Raduchel ,  Norbert Schwarz ,  Helmut Vorbruggen ,  Bernd Muller ,  Gerda Mannesmann ,  Olaf Loge ,  Ekkehardt Schillinger ,  Jorge Casals-Stenzel

    Inventor： Werner Skuballa ,  Bernd Raduchel ,  Norbert Schwarz ,  Helmut Vorbruggen ,  Bernd Muller ,  Gerda Mannesmann ,  Olaf Loge ,  Ekkehardt Schillinger ,  Jorge Casals-Stenzel

    IPC: A61K31/557 ,  A61K31/34 ,  A61K31/343 ,  A61K31/5575 ,  A61P7/02 ,  A61P7/10 ,  A61P9/06 ,  A61P9/12 ,  A61P43/00 ,  C07C405/00 ,  C07D307/935 ,  C07D307/937 ,  C07D307/93

    CPC classification number: C07D307/937 ,  C07C405/00 ,  Y10S514/821 ,  Y10S514/822 ,  Y10S514/869

    Abstract: Prostane derivatives of the formula ##STR1## wherein R.sub.1 is OR.sub.2 or NHR.sub.3 ;R.sub.2 is hydrogen, C.sub.1-10 alkyl, C.sub.4-10 cycloalkyl, C.sub.6-10 aryl, or a 5 or 6 membered heterocyclic ring having 1-3 hetero atoms selected from O, N and S;R.sub.3 is the residue of a hydrocarbon carboxylic or sulfonic acid of 1-15 carbon atoms;W is (a) an OH-substituted methylene group, (b) a ##STR2## wherein the OH-groups in (a) or (b) can be in the .alpha.- or .beta.-position, or (c) such a group wherein the H atom of the OH group is replaced by the residue of a hydrocarbon carboxylic or sulfonic acid of 1-15 carbon atoms or by a conventional etherifying OH-blocking group;R.sub.4 is OH or hydroxy whose H atom is replaced as defined for W; andR.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11 each independently is hydrogen or alkyl of 1-5 carbon atoms; or R.sub.9 and R.sub.10 together represent a direct bond; and, when R.sub.11 is alkyl, R.sub.10 can also be chlorine;and, for a derivative wherein R.sub.2 is hydrogen, the salts thereof with physiologically compatible bases,have improved prostaglandin activity.

    Abstract translation: 其中R1为OR2或NHR3的式（Ⅰ）所示的前驱体衍生物; R2是氢，C1-10烷基，C4-10环烷基，C6-10芳基或具有1-3个选自O，N和S的杂原子的5或6元杂环; R3是1-15个碳原子的烃羧酸或磺酸的残基; W是（a）OH-取代的亚甲基，（b）其中（a）或（b）中的OH基可以是α或β-位，或（c）这样的基团 其中OH基团的H原子被1-15个碳原子的烃羧酸或磺酸的残基或通过常规的醚化OH-封闭基团取代; R4是OH或羟基，其H原子被替换为W定义; R 5，R 6，R 7，R 8，R 9，R 10和R 11各自独立地为氢或1-5个碳原子的烷基; 或R 9和R 10一起代表直接键; 当R 11为烷基时，R 10也可为氯; 并且对于其中R 2是氢的衍生物，其与生理上相容的碱的盐具有改善的前列腺素活性。

    INTRINSICALLY-SAFE BATTERY POWER SUPPLY FOR UNDERGROUND MINING
    6.
    发明申请
    INTRINSICALLY-SAFE BATTERY POWER SUPPLY FOR UNDERGROUND MINING 有权
    用于地下采矿的本质安全电池电源

    公开(公告)号：US20090142629A1

    公开(公告)日：2009-06-04

    申请号：US12341745

    申请日：2008-12-22

    Applicant: Jens Titschert ,  Norbert Schwarz ,  Jorg Wagener

    Inventor： Jens Titschert ,  Norbert Schwarz ,  Jorg Wagener

    IPC: H01M12/00

    CPC classification number: H01M2/34 ,  H01M2/0267 ,  H01M2/0275 ,  H01M2/0443 ,  H01M2/06 ,  H01M2/1094 ,  H01M2/32 ,  H01M10/052 ,  H01M10/0565 ,  H01M10/46 ,  H02J7/0052 ,  Y02E60/122 ,  Y10T29/49108

    Abstract: An intrinsically-safe battery power supply for electrical equipment in underground mining and in other areas exposed to the danger of explosion is disclosed. The power supply includes at least one chargeable storage battery cell disposed in a battery housing. At least one storage battery cell comprises a chargeable lithium storage battery cell and the battery housing is configured to be pressure-resistant and to receive all lithium storage battery cells in a manner so as to be protected from explosion. The pressure-resistant configuration of the battery housing enables the use of lithium storage battery cells in underground mining. Once the battery power supply fulfils all requirements of ignition protection certification, even modern types of lithium storage battery cell can be disposed in the battery housing.

    Abstract translation: 公开了一种用于地下采矿和其他暴露于爆炸危险区域的电气设备的本质安全电池电源。 电源包括设置在电池壳体中的至少一个可充电蓄电池。 至少一个蓄电池单元包括可充电的锂蓄电池单元，并且所述电池壳体被配置为耐压并且以能够防止爆炸的方式接收所有锂蓄电池单元。 电池壳体的耐压构造使得能够在地下采矿中使用锂蓄电池。 一旦电池电源满足点火保护认证的所有要求，即使现代类型的锂蓄电池可以放置在电池外壳中。

    Carbacyclins, process for the preparation thereof, and use thereof as medicinal agents
    7.
    发明授权
    Carbacyclins, process for the preparation thereof, and use thereof as medicinal agents 失效
    卡巴菌素，其制备方法及其作为药剂的用途

    公开(公告)号：US5124343A

    公开(公告)日：1992-06-23

    申请号：US141233

    申请日：1988-01-06

    Applicant: Helmut Vorbrueggen ,  Hernd Raduechel ,  Werner Skuballa ,  Norbert Schwarz ,  Jorge Casals-Stenzel ,  Gerda Mannesmann ,  Michael H. Town

    Inventor： Helmut Vorbrueggen ,  Hernd Raduechel ,  Werner Skuballa ,  Norbert Schwarz ,  Jorge Casals-Stenzel ,  Gerda Mannesmann ,  Michael H. Town

    IPC: C07C45/59 ,  C07C57/26 ,  C07C57/60 ,  C07C405/00 ,  C07D263/14 ,  C07D317/72 ,  C07F9/40

    CPC classification number: C07D317/72 ,  C07C405/0083 ,  C07C45/59 ,  C07C57/26 ,  C07C57/60 ,  C07D263/14 ,  C07F9/4018

    Abstract: The invention relates to carbacyclins of general Formula I ##STR1## wherein R.sub.1 is the residue CH.sub.2 OH or ##STR2## with R.sub.2 meaning a hydrogen atom, an alkyl, cycloalkyl, aryl residue, a ##STR3## or heterocyclic residue, or R.sub.1 is the residue ##STR4## with R.sub.3 meaning an alkanoyl or alkanesulfonyl residue of respectively 1-10 carbon atoms or the residue R.sub.2, orR.sub.1 is the residue ##STR5## wherein m is the number 1 or 2, X is an oxygen atom or a CH.sub.2 -group,A is a trans--CH.dbd.CH- or --.tbd.C--group,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the .alpha.- or .beta.- position,n is the number 1, 2, or 3,D is a straight-chain alkylene group of 1-5 carbon atoms,E is a --C.tbd.C---bond or a --CR.sub.6 =CR.sub.7 --group wherein R.sub.6 and R.sub.7 are different from each other and mean a hydrogen atom or an alkyl group of 1-5 carbon atoms or a hydrogen atom or a halogen atom, preferably chlorine,R.sub.4 is an alkyl, cycloalkyl, or optionally substituted arly group, or a heterocyclic group,R.sub.5 is a free or functionally modified hydroxy group, andif R.sub.2 means a hydrogen atom, the salts thereof with physiologically compatible bases;to processes for the preparation thereof, and to the use thereof as blood-pressure-lowering agents.

    Abstract translation: 本发明涉及通式I的碳霉素，其中R 1是残基CH 2 OH或R 2，其中R 2表示氢原子，烷基，环烷基，芳基，芳基或杂环残基，或者R 1是 残基其中R3表示分别为1-10个碳原子的烷酰基或烷磺酰基残基或残基R2，或R1为残基，其中m为数1或2，X为氧原子或CH2- 基团，A是反式-CH = CH-或 - 3BOND C-基团，W是游离或官能改性的羟基亚甲基基团，其中OH-基团可以是α或β位置，n是数1，2 或3，D是1-5个碳原子的直链亚烷基，E是-C3OND C键或-CR6 = CR7-基团，其中R6和R7彼此不同，意指氢 原子或1-5个碳原子的烷基或氢原子或卤素原子，优选氯，R4是烷基，环烷基或任选取代的芳基或杂环基团 p，R5是游离或功能改性的羟基，如果R 2表示氢原子，则其与生理上相容的碱的盐; 其制备方法及其作为降血压剂的用途。

    .DELTA..sup.8,9 -Prostaglandin derivatives, their preparation and use as medicinal agents
    9.
    发明授权
    .DELTA..sup.8,9 -Prostaglandin derivatives, their preparation and use as medicinal agents 失效
    DELTA 8,9-前列腺素衍生物，其制备和用作药物

    公开(公告)号：US4560786A

    公开(公告)日：1985-12-24

    申请号：US391734

    申请日：1982-06-24

    Applicant: Werner Skuballa ,  Bernd Raduechel ,  Norbert Schwarz ,  Helmut Vorbrueggen ,  Walter Elger ,  Olaf Loge ,  Michael-Harold Town

    Inventor： Werner Skuballa ,  Bernd Raduechel ,  Norbert Schwarz ,  Helmut Vorbrueggen ,  Walter Elger ,  Olaf Loge ,  Michael-Harold Town

    IPC: A61K31/045 ,  A61K31/557 ,  A61K31/5575 ,  A61P25/04 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00 ,  C07C177/00

    CPC classification number: C07C405/0016 ,  C07C405/00 ,  C07C405/0041

    Abstract: .DELTA..sup.8,9 -Prostane derivatives of Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH or ##STR2## wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is ##STR3## wherein R.sub.3 is an acid residue or R.sub.2 ; A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH;B is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C--W is a free or functionally modified hydroxymethylene group or free or functionally modified ##STR4## wherein the OH--group can be in the .alpha.-- or .beta.-- position; D and E jointly are a direct bond orD is straight chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen, sulfur, a direct bond, --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 --, wherein R.sub.6 and R.sub.7 differ from each other and each is hydrogen, chlorine or alkyl;R.sub.4 is free or functionally modified hydroxy andR.sub.5 is an optionally substituted aliphatic group, cycloalkyl, optionally substituted aryl, or a heterocyclic group, and when R.sub.2 is hydrogen, physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g. luteolytic and abortifacient activities.

    Abstract translation: DELTA 8,9-式I的前驱体衍生物其中R 1是CH 2 OH或其中R 2是氢，烷基，环烷基，芳基或杂环残基; 或R 1为，其中R 3为酸残基或R 2; A是-CH 2 -CH 2 - 或顺式-CH = CH; B是-CH 2 -CH 2 - ，反式-CH = CH-或-C 3BOND C-W是游离或官能改性的羟基亚甲基或游离或官能改性的“IMAGE”，其中OH-基团可以是α或β - 位置 D和E共同是直接键合，或D是可以任选被氟原子取代的1-10个碳原子的直链或支链亚烷基或亚烯基，并且E是氧，硫，直接键，-C 3 D或 -CR 6 = CR 7 - ，其中R 6和R 7彼此不同，各自为氢，氯或烷基; R4是游离的或官能改性的羟基，R 5是任选取代的脂族基，环烷基，任选取代的芳基或杂环基，当R 2是氢时，其与碱的生理上相容的盐具有有价值的药理学性质。 luteolytic和流产活动。

    9-Fluoroprostaglandin derivatives, and use as medicinal agents
    10.
    发明授权
    9-Fluoroprostaglandin derivatives, and use as medicinal agents 失效
    9-氟前列腺素衍生物，用作药物

    公开(公告)号：US4454339A

    公开(公告)日：1984-06-12

    申请号：US395448

    申请日：1982-07-06

    Applicant: Werner Skuballa ,  Bernd Raduechel ,  Norbert Schwarz ,  Helmut Vorbrueggen ,  Walter Elger ,  Olaf Loge ,  Michael-Harold Town

    Inventor： Werner Skuballa ,  Bernd Raduechel ,  Norbert Schwarz ,  Helmut Vorbrueggen ,  Walter Elger ,  Olaf Loge ,  Michael-Harold Town

    IPC: A61K31/557 ,  A61K31/5575 ,  A61P43/00 ,  C07C67/00 ,  C07C401/00 ,  C07C405/00 ,  C07C177/00

    CPC classification number: C07C405/00 ,  C07C405/0016 ,  C07C405/0041

    Abstract: 9-Fluoroprostane derivatives of Formula I ##STR1## wherein R.sub.1 is CH.sub.2 OH or ##STR2## wherein R.sub.2 is hydrogen, alkyl, cycloalkyl, aryl, or a heterocyclic residue; or R.sub.1 is the residue ##STR3## wherein R.sub.3 is an acid residue or R.sub.2 and A is --CH.sub.2 --CH.sub.2 -- or cis--CH.dbd.CH--,B is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH-- or --C.tbd.C,W is a free or functionally modified hydroxymethylene group wherein the OH-group can be in the .alpha.- or .beta.-position,D and E jointly are a direct bond orD is straight-chain or branched alkylene or alkenylene of 1-10 carbon atoms which can optionally be substituted by fluorine atoms, and E is oxygen or sulfur, a direct bond, --C.tbd.C-- or --CR.sub.6 .dbd.CR.sub.7 -- wherein R.sub.6 and R.sub.7 differ from each other and each is hydrogen, chlorine, or alkyl,R.sub.4 is a free or functionally modified hydroxy group, andR.sub.5 is hydrogen, an optionally substituted aliphatic group, e.g., alkyl or halosubstituted alkyl, cycloalkyl, optionally substituted aryl or a heterocyclic group, and, when R.sub.2 is H, physiologically compatible salts thereof with bases,have valuable pharmacological properties, e.g., as luteolytics or abortifacients.

    Abstract translation: 其中R 1是CH 2 OH或其中R 2是氢，烷基，环烷基，芳基或杂环残基的式I的1-氟代衍生物（Ⅰ） 或R1是残基，其中R3是酸残基或R2和A是-CH2-CH2-或顺式-CH = CH-，B是-CH2-CH2-，反式-CH = CH-或-C3BOND C，W是游离的或官能改性的羟基亚甲基，其中OH基可以是α-或β-位，D和E共同是直接键，或D是1-10的直链或支链亚烷基或亚烯基 可以任选被氟原子取代的碳原子，E是氧或硫，直接键，-C 3 D或-CR 6 = CR 7 - ，其中R 6和R 7彼此不同，各自是氢，氯或烷基 R4是游离的或官能改性的羟基，R5是氢，任意取代的脂族基团，例如烷基或卤代取代的烷基，环烷基，任选取代的芳基或杂环基，当R 2是H时，其生理上相容的盐 具有碱性，具有有价值的药理学性质，例如作为纤溶素或流产。

Patent Agency Ranking